Clinical trials: Advanced Malignant Tumor
Advanced Solid Tumors
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
This is an open-label, two-part, multicenter study to evaluate the safety and tolerability of DS-8201a in participants with advanced solid malignant tumors.
- Trial name
- NCT02564900
- Testing
- DS-8201a (DP1), DS-8201a (DP2), DS-8201a (DP)
- Where
- 14 sites in United States, Japan
- Volunteers
- 292 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Solid Tumor, Colorectal Cancer
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
This will be a Phase 1, open-label study of DS-7423 to assess its safety and tolerability, identify a RP2D, (recommended Phase 2 Dose) and assess its Pharmacokinetics (PK) (what your body does to process the drugs and how your…
- Conditions
- Solid Tumor, Colorectal Cancer, Endometrial Cancer
- Trial name
- NCT01364844
- Testing
- DS-7423
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Daiichi Sankyo
Esophageal Neoplasms, Hepatocellular Carcinoma
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.
- Conditions
- Esophageal Neoplasms, Hepatocellular Carcinoma, Colorectal Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00057395
- Testing
- Aroplatin (Liposomal NDDP, L-NDDP)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Aronex Pharmaceuticals
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
This research trial studies comprehensive genomic analysis in tissue samples from patients with non-small cell lung cancer that has come back or is stage IV.
- Trial name
- NCT02178163
- Testing
- cytology specimen collection procedure, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 619 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lung Cancer, Non-small Cell, EGFR Gene Mutation
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Lung cancer is currently the world's largest malignant tumor for cancer-related deaths with non-small cell lung cancer (NSCLC) accounting for 80%-85%.
- Conditions
- Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation, Primary Resistance
- Trial name
- PRECISE (NCT05598528)
- Testing
- Genomic profiles detection, circulating tumor DNA detection
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Second Xiangya Hospital of Central South University
Breast Cancer, Endometrial Cancer
High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma
RATIONALE: Some hormones can stimulate the growth of some types of cancer cells. Hormone therapy using megestrol may fight cancer by reducing the production of these hormones.
- Conditions
- Breast Cancer, Endometrial Cancer, Malignant Mesothelioma
- Trial name
- NCT00002465
- Testing
- megestrol acetate
- Where
- United States
- Sponsor
- St. Vincent Medical Center - Los Angeles
Solid Tumor
Clinical Study of ICP-192 in Solid Tumors Patients
Open-label, non-randomized, Phase I/IIa, dose-escalating, dose-extension, first-in-man study.
- Trial name
- NCT03758664
- Testing
- ICP-192
- Where
- 7 sites in China
- Volunteers
- 56 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Solid Tumor
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral…
- Trial name
- NCT06797336
- Testing
- PT0253, Chemotherapy Combination 1, Chemotherapy Combination 2
- Where
- 15 sites in United States, South Korea
- Volunteers
- 300 people
- Sponsor
- PAQ Therapeutics, Inc.
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
This phase I trial studies the best dose of sonidegib when given together with pembrolizumab and to see how well they work in treating patients with solid tumor that has spread to other places in the body (advanced).
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04007744
- Testing
- Pembrolizumab, Sonidegib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Advanced Solid Tumor
A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer
This is a single-arm, open-label, clinical pharmacology study to evaluate safety and efficacy of oncolytic virus injection(RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer.
- Trial name
- NCT05205421
- Testing
- Oncolytic Virus Injection(RT-01)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Melanoma
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion
The goal of the first phase of this clinical research study is to find the highest tolerable dose of decitabine and peginterferon alfa-2b that can be given in combination to patients with melanoma.
- Trial name
- NCT00791271
- Testing
- Decitabine, Pegylated Interferon Alpha-2b
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
This is a phase 1 study in which 2 to 72 patients with advanced cancer will receive oral doses of rigosertib, a new investigational (unapproved) anti-cancer drug.
- Trial name
- NCT01168011
- Testing
- rigosertib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Traws Pharma, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003710
- Testing
- irinotecan hydrochloride, mitomycin C
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Solid Tumors, Advanced Cancer
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion…
- Conditions
- Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer
- Trial name
- SPARTA (NCT03175224)
- Testing
- APL-101 Oral Capsules
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 497 people
- Sponsor
- Apollomics Inc.
Solid Tumors (Phase 1), RAS Mutation
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
The goal of this clinical trial is to learn determine if AN9025 is safe and tolerable to treat solid cancer tumors with specific genetic mutations.
- Trial name
- NCT07252479
- Testing
- AN9025 oral capsule
- Where
- 3 sites in United States
- Volunteers
- 118 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Advanced Solid Tumor
A Study of YL242 in Subjects With Advanced Solid Tumors
This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
- Trial name
- NCT07197827
- Testing
- YL242, YL242; Pembrolizumab, YL242; 5-FU; LV
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 424 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Malignant Neoplasm
NV-001 in the Treatment of Advanced Solid Tumors
This study is a single-center, open, dose-escalation Phase I clinical study. It is designed to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of treating NV-001, a king of hybrid-membrane-based tumor…
- Trial name
- NCT06051760
- Testing
- NV-001
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Solid Tumor Cancer
SB-715992 In Combination With Docetaxel In Patients With Solid Tumors
The purpose of this study is to determine the dose regimen of SB-715992 in combination with docetaxel in patients with solid tumors.
- Trial name
- NCT00169520
- Testing
- docetaxel, SB-715992
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma
Ivonescimab in the Treatment of Multiple Advanced Tumors
The goal of this clinical trial is to learn if Ivonescimab works to treat advanced rare tumors including cohort 1: PAGET's disease of scrotum with infiltrating sweat gland carcinoma.
- Conditions
- Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma
- Trial name
- NCT06683846
- Testing
- Ivocizumab
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Fudan University
Advanced Malignant Solid Neoplasm, Recurrent Melanoma
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with riluzole in treating patients with solid tumors or melanoma that has spread to other places in the body and usually cannot…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Melanoma, Refractory Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01303341
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Riluzole
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.